B Boeve

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. pmc TREM2 in neurodegeneration: evidence for association of the p.R47H variant with frontotemporal dementia and Parkinson's disease
    Sruti Rayaprolu
    Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA
    Mol Neurodegener 8:19. 2013
  2. pmc Clinicopathologic correlations in 172 cases of rapid eye movement sleep behavior disorder with or without a coexisting neurologic disorder
    B F Boeve
    Department of Neurology, Mayo Clinic, Rochester, MN 55905, USA
    Sleep Med 14:754-62. 2013
  3. pmc Validation of the Mayo Sleep Questionnaire to screen for REM sleep behavior disorder in a community-based sample
    Bradley F Boeve
    Department of Neurology, Mayo Clinic College of Medicine, Rochester, MN and Jacksonville, FL 55905, USA
    J Clin Sleep Med 9:475-80. 2013
  4. doi Idiopathic REM sleep behaviour disorder in the development of Parkinson's disease
    Bradley F Boeve
    Department of Neurology and Center for Sleep Medicine, Mayo Clinic, Rochester, MN, USA
    Lancet Neurol 12:469-82. 2013
  5. pmc Similar clinical and neuroimaging features in monozygotic twin pair with mutation in progranulin
    E McDade
    Department of Neurology, Mayo Clinic, Rochester, MN, USA
    Neurology 78:1245-9. 2012
  6. pmc Characterization of frontotemporal dementia and/or amyotrophic lateral sclerosis associated with the GGGGCC repeat expansion in C9ORF72
    Bradley F Boeve
    Department of Neurology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Brain 135:765-83. 2012
  7. ncbi A review of the non-Alzheimer dementias
    Bradley F Boeve
    Division of Behavioral Neurology, Department of Neurology, Mayo Clinic, Rochester, Minnesota 55905, USA
    J Clin Psychiatry 67:1985-2001; discussion 1983-4. 2006
  8. ncbi Links between frontotemporal lobar degeneration, corticobasal degeneration, progressive supranuclear palsy, and amyotrophic lateral sclerosis
    Bradley F Boeve
    Division of Behavioral Neurology, Department of Neurology, Mayo Clinic, Rochester, MN 55905, USA
    Alzheimer Dis Assoc Disord 21:S31-8. 2007
  9. doi Progressive supranuclear palsy
    Bradley F Boeve
    Division of Behavioral Neurology, Department of Neurology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Parkinsonism Relat Disord 18:S192-4. 2012
  10. ncbi Parkinson-related dementias
    Bradley F Boeve
    Division of Behavioral Neurology, Department of Neurology, Mayo Clinic, Rochester, MN 55905, USA
    Neurol Clin 25:761-81, vii. 2007

Detail Information

Publications94

  1. pmc TREM2 in neurodegeneration: evidence for association of the p.R47H variant with frontotemporal dementia and Parkinson's disease
    Sruti Rayaprolu
    Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA
    Mol Neurodegener 8:19. 2013
    ..With this in mind we set out to assess the genetic association of the Alzheimer's disease-related risk variant in TREM2 (rs75932628, p.R47H) with other related neurodegenerative disorders...
  2. pmc Clinicopathologic correlations in 172 cases of rapid eye movement sleep behavior disorder with or without a coexisting neurologic disorder
    B F Boeve
    Department of Neurology, Mayo Clinic, Rochester, MN 55905, USA
    Sleep Med 14:754-62. 2013
    ..To determine the pathologic substrates in patients with rapid eye movement (REM) sleep behavior disorder (RBD) with or without a coexisting neurologic disorder...
  3. pmc Validation of the Mayo Sleep Questionnaire to screen for REM sleep behavior disorder in a community-based sample
    Bradley F Boeve
    Department of Neurology, Mayo Clinic College of Medicine, Rochester, MN and Jacksonville, FL 55905, USA
    J Clin Sleep Med 9:475-80. 2013
    ..To validate a questionnaire focused on REM sleep behavior disorder (RBD) in a community-based sample...
  4. doi Idiopathic REM sleep behaviour disorder in the development of Parkinson's disease
    Bradley F Boeve
    Department of Neurology and Center for Sleep Medicine, Mayo Clinic, Rochester, MN, USA
    Lancet Neurol 12:469-82. 2013
    ....
  5. pmc Similar clinical and neuroimaging features in monozygotic twin pair with mutation in progranulin
    E McDade
    Department of Neurology, Mayo Clinic, Rochester, MN, USA
    Neurology 78:1245-9. 2012
    ..To report the phenotypic characterization of monozygotic twins with mutations encoding progranulin (PGRN)...
  6. pmc Characterization of frontotemporal dementia and/or amyotrophic lateral sclerosis associated with the GGGGCC repeat expansion in C9ORF72
    Bradley F Boeve
    Department of Neurology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Brain 135:765-83. 2012
    ..While variability exists, most cases with this mutation have a characteristic spectrum of demographic, clinical, neuropsychological, neuroimaging and especially neuropathological findings...
  7. ncbi A review of the non-Alzheimer dementias
    Bradley F Boeve
    Division of Behavioral Neurology, Department of Neurology, Mayo Clinic, Rochester, Minnesota 55905, USA
    J Clin Psychiatry 67:1985-2001; discussion 1983-4. 2006
    ..To review the clinical features, neuropathologic features, clinical course, differential diagnosis, evaluation, and management strategies of the primary non-Alzheimer degenerative and prion disorders that cause dementia...
  8. ncbi Links between frontotemporal lobar degeneration, corticobasal degeneration, progressive supranuclear palsy, and amyotrophic lateral sclerosis
    Bradley F Boeve
    Division of Behavioral Neurology, Department of Neurology, Mayo Clinic, Rochester, MN 55905, USA
    Alzheimer Dis Assoc Disord 21:S31-8. 2007
    ....
  9. doi Progressive supranuclear palsy
    Bradley F Boeve
    Division of Behavioral Neurology, Department of Neurology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Parkinsonism Relat Disord 18:S192-4. 2012
    ....
  10. ncbi Parkinson-related dementias
    Bradley F Boeve
    Division of Behavioral Neurology, Department of Neurology, Mayo Clinic, Rochester, MN 55905, USA
    Neurol Clin 25:761-81, vii. 2007
    ....
  11. doi The multiple phenotypes of corticobasal syndrome and corticobasal degeneration: implications for further study
    Bradley F Boeve
    Division of Behavioral Neurology, Department of Neurology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    J Mol Neurosci 45:350-3. 2011
    ..The clinicopathologic heterogeneity in CBS/CBD and the implications of this heterogeneity on clinical practice, on understanding the focal/asymmetric cerebral degeneration syndromes, and on future research are all reviewed...
  12. ncbi Clinical, diagnostic, genetic and management issues in dementia with Lewy bodies
    Bradley F Boeve
    Division of Behavioral Neurology, Department of Neurology, Mayo Clinic, Rochester, MN 559505, U S A
    Clin Sci (Lond) 109:343-54. 2005
    ..In this review, the clinical features, diagnostic criteria, genetics and treatment issues relating to DLB will be discussed, in which a comprehensive approach to the diagnosis and management is emphasized...
  13. ncbi Absence of rapid eye movement sleep behavior disorder in 11 members of the pallidopontonigral degeneration kindred
    Bradley F Boeve
    Department of Neurology, Mayo Clinic College of Medicine, Rochester, Minn 55905, USA
    Arch Neurol 63:268-72. 2006
    ..There are no reports on the possible association of rapid eye movement sleep without atonia and RBD with any familial tauopathy...
  14. pmc Refining frontotemporal dementia with parkinsonism linked to chromosome 17: introducing FTDP-17 (MAPT) and FTDP-17 (PGRN)
    Bradley F Boeve
    Division of Behavioral Neurology, Department of Neurology, Mayo Clinic, 200 First St SW, Rochester, Minnesota, 55905, USA
    Arch Neurol 65:460-4. 2008
    ..Our findings describe an intriguing oddity of nature in which 2 genes can cause a similar phenotype through apparently different mechanisms yet reside so near to each other on the same chromosome...
  15. pmc REM sleep behavior disorder: Updated review of the core features, the REM sleep behavior disorder-neurodegenerative disease association, evolving concepts, controversies, and future directions
    Bradley F Boeve
    Department of Neurology and Center for Sleep Medicine, Mayo Clinic, Rochester, Minnesota, USA
    Ann N Y Acad Sci 1184:15-54. 2010
    ..Planning for future therapies that impact patients with idiopathic RBD is reviewed in detail...
  16. ncbi Frontotemporal dementia and parkinsonism associated with the IVS1+1G->A mutation in progranulin: a clinicopathologic study
    Bradley F Boeve
    Department of Neurology, Mayo Clinic Rochester, MN 55905, USA
    Brain 129:3103-14. 2006
    ..These findings suggest that the insR352 PSEN1 is not pathogenic, and the IVS1+1G-->A mutation in PGRN causes FTDP associated with FTLD-U pathology and represents a new class of neurodegenerative disease--the 'hypoprogranulinopathies'...
  17. ncbi Pathophysiology of REM sleep behaviour disorder and relevance to neurodegenerative disease
    B F Boeve
    Department of Neurology, 6Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Brain 130:2770-88. 2007
    ..Furthermore, longitudinal studies in patients with idiopathic RBD are warranted to characterize the natural history of such patients and prepare for future therapeutic trials...
  18. pmc Insights into REM sleep behavior disorder pathophysiology in brainstem-predominant Lewy body disease
    B F Boeve
    Department of Neurology, Mayo Clinic College of Medicine, Rochester, MN, USA
    Sleep Med 8:60-4. 2007
    ..Additional cases of idiopathic RBD with neuropathologic examination may help clarify which key brainstem structures are involved...
  19. ncbi Evidence for cholinesterase-inhibitor therapy for dementia associated with Parkinson's disease
    Bradley F Boeve
    Division of Behavioral Neurology, Department of Neurology, Mayo Clinic College of Medicine, Rochester, Minnesota, 200 First Street SW, Rochester, Minnesota 55905, USA
    Lancet Neurol 4:137-8. 2005
  20. doi Mild cognitive impairment associated with underlying Alzheimer's disease versus Lewy body disease
    Bradley F Boeve
    Division of Behavioral Neurology, Department of Neurology, and Center for Sleep Medicine, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Parkinsonism Relat Disord 18:S41-4. 2012
    ..The early data suggests that differentiating underlying AD vs LBD in the MCI phase will be feasible...
  21. ncbi Current management of sleep disturbances in dementia
    Bradley F Boeve
    Mayo Sleep Disorders Center, Department of Neurology, Mayo Alzheimer s Disease Research Center, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Curr Neurol Neurosci Rep 2:169-77. 2002
    ....
  22. ncbi Mild cognitive impairment in the oldest old
    B Boeve
    Department of Neurology, Mayo Alzheimer s Disease Research Center, Mayo Clinic, Rochester, MN 55905, USA
    Neurology 60:477-80. 2003
    ..No data exist on whether the syndrome of amnestic mild cognitive impairment occurs in the oldest old, or if the relationships for functional status and neuropsychometric performance based on clinical diagnosis hold true in this age group...
  23. ncbi Corticobasal degeneration and frontotemporal dementia presentations in a kindred with nonspecific histopathology
    B F Boeve
    Department of Neurology, Mayo Clinic, Rochester, MN 55905, USA
    Dement Geriatr Cogn Disord 13:80-90. 2002
    ....
  24. ncbi Progressive nonfluent aphasia and subsequent aphasic dementia associated with atypical progressive supranuclear palsy pathology
    B Boeve
    Department of Neurology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Eur Neurol 49:72-8. 2003
    ..Hence, PSP can present clinically as an atypical dementing syndrome dominated by progressive aphasia/apraxia of speech...
  25. pmc Validation of the Mayo Sleep Questionnaire to screen for REM sleep behavior disorder in an aging and dementia cohort
    Bradley F Boeve
    Department of Neurology, Mayo Clinic, College of Medicine, Rochester, MN 55905, USA
    Sleep Med 12:445-53. 2011
    ..To validate a questionnaire focused on rapid eye movement sleep (REM) sleep behavior disorder (RBD) among participants in an aging and dementia cohort...
  26. ncbi Association of REM sleep behavior disorder and neurodegenerative disease may reflect an underlying synucleinopathy
    B F Boeve
    Sleep Disorders Center and Department of Neurology, Mayo Clinic Rochester, Rochester, Minnesota 55905, USA
    Mov Disord 16:622-30. 2001
    ..In the setting of degenerative dementia and/or parkinsonism, we hypothesize that RBD is a manifestation of an evolving synucleinopathy...
  27. ncbi Corticobasal degeneration and its relationship to progressive supranuclear palsy and frontotemporal dementia
    Bradley F Boeve
    Division of Behavioral Neurology, Department of Neurology, and Alzheimer s Disease Research Center, Mayo Clinic, Rochester, MN 55905, USA
    Ann Neurol 54:S15-9. 2003
  28. ncbi Synucleinopathy pathology and REM sleep behavior disorder plus dementia or parkinsonism
    B F Boeve
    Department of Neurology, Mayo Clinic, Rochester, Minneapolis, MN 55905, USA
    Neurology 61:40-5. 2003
    ..To determine if synucleinopathy pathology is related to REM sleep behavior disorder (RBD) plus dementia or parkinsonism...
  29. ncbi Longitudinal characterization of two siblings with frontotemporal dementia and parkinsonism linked to chromosome 17 associated with the S305N tau mutation
    Bradley F Boeve
    Department of Neurology, Mayo Clinic College of Medicine, Rochester, Minnesota, MN 55905, USA
    Brain 128:752-72. 2005
    ..These findings have implications for future drug trial development in FTDP-17 and the sporadic tauopathies...
  30. ncbi REM sleep behavior disorder in Parkinson's disease and dementia with Lewy bodies
    Bradley F Boeve
    Sleep Disorders Center, Department of Neurology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    J Geriatr Psychiatry Neurol 17:146-57. 2004
    ..The evolving data suggests that RBD may have clinical diagnostic and pathophysiologic significance in isolation and when associated with neurodegenerative disease...
  31. ncbi Neuropathologic outcome of mild cognitive impairment following progression to clinical dementia
    Gregory A Jicha
    Alzheimer s Disease Research Center and Department of Neurology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Arch Neurol 63:674-81. 2006
    ..The pathologic outcome of patients diagnosed with mild cognitive impairment (MCI) following progression to dementia is poorly understood...
  32. pmc Prominent phenotypic variability associated with mutations in Progranulin
    Brendan J Kelley
    Department of Neurology, Mayo Clinic, Rochester, MN 55905, USA
    Neurobiol Aging 30:739-51. 2009
    ..Some kindreds with PGRN mutations exhibited lateralized topography of degeneration across all affected individuals...
  33. ncbi A 75-year-old man with cognitive impairment and gait changes
    Carol F Lippa
    Department of Neurology, Drexel University College of Medicine, Philadelphia, PA, USA
    Neurology 69:1183-9. 2007
  34. pmc Cognitive and noncognitive neurological features of young-onset dementia
    Brendan J Kelley
    Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA
    Dement Geriatr Cogn Disord 27:564-71. 2009
    ..Limited data exist regarding clinical features associated with dementia prior to the age of 45...
  35. pmc Rates of cerebral atrophy differ in different degenerative pathologies
    Jennifer L Whitwell
    Department of Radiology, Mayo Clinic Rochester, Rochester, MN 55905, USA
    Brain 130:1148-58. 2007
    ....
  36. pmc 1H magnetic resonance spectroscopy, cognitive function, and apolipoprotein E genotype in normal aging, mild cognitive impairment and Alzheimer's disease
    Kejal Kantarci
    Department of Diagnostic Radiology, Mayo Clinic, Rochester, Minnesota 55901, USA
    J Int Neuropsychol Soc 8:934-42. 2002
    ..Among 1H-MRS measurements, the NAA/MI ratio maybe the most efficient predictor of memory and cognitive function in patients with MCI and AD...
  37. pmc Voxel-based morphometry in frontotemporal lobar degeneration with ubiquitin-positive inclusions with and without progranulin mutations
    Jennifer L Whitwell
    Division of Behavioral Neurology, Department of Neurology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Arch Neurol 64:371-6. 2007
    ..Mutations in the progranulin gene (PGRN) have recently been identified as a cause of frontotemporal lobar degeneration with ubiquitin-positive inclusions (FTLD-U) in some families...
  38. doi Young-onset dementia: demographic and etiologic characteristics of 235 patients
    Brendan J Kelley
    Department of Neurology, Mayo Clinic, Rochester, MN 55905, USA
    Arch Neurol 65:1502-8. 2008
    ..Few data exist regarding the demographics characterizing this population or the etiologic diagnoses among those affected...
  39. pmc Alzheimer disease-like phenotype associated with the c.154delA mutation in progranulin
    Brendan J Kelley
    Department of Neurology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Arch Neurol 67:171-7. 2010
    ..To characterize a kindred with a familial neurodegenerative disorder associated with a mutation in progranulin (PGRN), with emphasis on the unique clinical features in this kindred...
  40. ncbi Neuropathologic features of frontotemporal lobar degeneration with ubiquitin-positive inclusions with progranulin gene (PGRN) mutations
    Keith A Josephs
    Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA
    J Neuropathol Exp Neurol 66:142-51. 2007
    ..On the other hand, there is no histopathologic feature or combination of features that is pathognomonic. Neuronal intranuclear inclusions are virtually always present, but they can be detected in PGRN(-) cases...
  41. pmc Comparative diagnostic utility of different MR modalities in mild cognitive impairment and Alzheimer's disease
    Kejal Kantarci
    Department of Diagnostic Radiology, Mayo Clinic, Rochester, Minn, USA
    Dement Geriatr Cogn Disord 14:198-207. 2002
    ..Selection of imaging measures used for clinical assessment or monitoring efficiency of therapeutic intervention should be tailored to the clinical stage of the disease...
  42. pmc Focal atrophy in dementia with Lewy bodies on MRI: a distinct pattern from Alzheimer's disease
    Jennifer L Whitwell
    Department of Radiology, Mayo Clinic, Rochester, MN 55905, USA
    Brain 130:708-19. 2007
    ..Damage to this network of structures in DLB may affect a number of different neurotransmitter systems which in turn may contribute to a number of the core clinical features of DLB...
  43. pmc 3D maps from multiple MRI illustrate changing atrophy patterns as subjects progress from mild cognitive impairment to Alzheimer's disease
    Jennifer L Whitwell
    Department of Radiology, Mayo Clinic, 200 1st St SW, Rochester, MN 55905, USA
    Brain 130:1777-86. 2007
    ..These results also suggest that 3D patterns of grey matter atrophy may help to predict the time to the first diagnosis of AD in subjects with aMCI...
  44. ncbi Argyrophilic grain disease in demented subjects presenting initially with amnestic mild cognitive impairment
    Gregory A Jicha
    Department of Neurology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA
    J Neuropathol Exp Neurol 65:602-9. 2006
    ..AGD is a common pathologic finding in subjects who have been diagnosed with amnestic MCI...
  45. ncbi Clinical-pathologic study of biomarkers in FTDP-17 (PPND family with N279K tau mutation)
    Zoe Arvanitakis
    Department of Neurology, Mayo Clinic, Jacksonville, FL, USA
    Parkinsonism Relat Disord 13:230-9. 2007
    ..Autopsy of six affected subjects showed frontotemporal degeneration with extensive tauopathy. Further studies of FTDP-17 patients are needed to replicate these findings...
  46. ncbi The effect of tau genotype on clinical features in FTDP-17
    Yasuhiko Baba
    Department of Neurology, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL 32224, USA
    Parkinsonism Relat Disord 11:205-8. 2005
    ..7; 95% confidence interval, 1.4-98.7; P=0.008). Our results suggest that tau genotype does not influence the disease course. However, it may predispose to a specific clinical sign in the early stage of FTDP-17...
  47. pmc The influence of apolipoprotein E genotype on visuospatial attention dissipates after age 80
    Selam Negash
    Department of Neurology, Mayo Clinic, USA
    Neuropsychology 23:81-9. 2009
    ..The dissipation of the APOE effect in old-old individuals at lower risk of AD suggests that visuospatial attention impairments seen as early as midlife in APOE-e4 carriers may be a preclinical marker of AD...
  48. doi Alzheimer's disease and corticobasal degeneration presenting as corticobasal syndrome
    William T Hu
    Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA
    Mov Disord 24:1375-9. 2009
    ..AD patients with clinical CBS have similar characteristics to CBD patients. Functional brain imaging may have greater utility than the clinical and neuropsychological features in differentiating AD presenting as CBS from CBD...
  49. pmc Age and apoE associations with complex pathologic features in Alzheimer's disease
    Gregory A Jicha
    Department of Neurology, Mayo Clinic, Rochester, MN, Jacksonville, FL, United States
    J Neurol Sci 273:34-9. 2008
    ....
  50. pmc Validation of the neuropathologic criteria of the third consortium for dementia with Lewy bodies for prospectively diagnosed cases
    Hiroshige Fujishiro
    Department of Pathology and Neuroscience, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL 32224, USA
    J Neuropathol Exp Neurol 67:649-56. 2008
    ....
  51. doi Frontotemporal dementia mimicking dementia with Lewy bodies
    Daniel O Claassen
    Department of Neurology, Mayo Clinic, Rochester, MN 55905, USA
    Cogn Behav Neurol 21:157-63. 2008
    ..Clinicopathologic studies are helpful in understanding the underlying neurodegenerative process in such cases...
  52. pmc Rapidly progressive young-onset dementia
    Brendan J Kelley
    Department of Neurology, Mayo Clinic, Rochester, MN 55905, USA
    Cogn Behav Neurol 22:22-7. 2009
    ..To characterize a cohort of individuals who have experienced rapidly progressive dementia with onset before age 45...
  53. pmc Rates of brain atrophy over time in autopsy-proven frontotemporal dementia and Alzheimer disease
    Jennifer L Whitwell
    Department of Radiology, Mayo Clinic, Rochester, MN 55905, USA
    Neuroimage 39:1034-40. 2008
    ..The trajectories of brain and ventricular changes were similar in AD and FTLD-U suggesting that it is independent of pathology, although subjects with FTLD-U show a more rapidly progressive decline...
  54. pmc Vegetables, unsaturated fats, moderate alcohol intake, and mild cognitive impairment
    Rosebud O Roberts
    Division of Epidemiology, Department of Health Sciences Research, Mayo Clinic, Rochester, MN 55905, USA roberts rosebud mayo edu
    Dement Geriatr Cogn Disord 29:413-23. 2010
    ..To investigate associations of the Mediterranean diet (MeDi) components and the MeDi score with mild cognitive impairment (MCI)...
  55. pmc Patterns of atrophy differ among specific subtypes of mild cognitive impairment
    Jennifer L Whitwell
    Department of Radiology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Arch Neurol 64:1130-8. 2007
    ..It follows, however, that subjects with MCI who have impairment in nonmemory domains may progress to non-AD degenerative dementias...
  56. pmc Imaging correlates of posterior cortical atrophy
    Jennifer L Whitwell
    Department of Radiology, Mayo Clinic, Rochester, MN 55905, USA
    Neurobiol Aging 28:1051-61. 2007
    ..1)H MRS suggested loss of neuronal integrity and glial activation in subjects with PCA and typical AD. The differing patterns of atrophy on MRI suggest that PCA should be considered a distinct entity from typical AD...
  57. ncbi Distinctive MRI findings in pallidopontonigral degeneration (PPND)
    Andrew R Frank
    Department of Neurology, Mayo Clinic College of Medicine, Rochester, MN, USA
    Neurology 68:620-1. 2007
  58. ncbi A prospective study of quality of life in adults with newly diagnosed high-grade gliomas: the impact of the extent of resection on quality of life and survival
    Paul D Brown
    Division of Radiation Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Neurosurgery 57:495-504; discussion 495-504. 2005
    ..To describe the quality of life (QOL) over time for adults with newly diagnosed high-grade gliomas and to examine the relationship between QOL and outcome data collected in three prospective cooperative group clinical trials...
  59. ncbi Correlation between antemortem magnetic resonance imaging findings and pathologically confirmed corticobasal degeneration
    Keith A Josephs
    Department of Neurology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Arch Neurol 61:1881-4. 2004
    ..Various pathologic findings, including corticobasal degeneration (CBD), progressive supranuclear palsy, and frontotemporal degenerations, underlie CBS...
  60. ncbi A preliminary fluorodeoxyglucose positron emission tomography study in healthy adults reporting dream-enactment behavior
    Richard J Caselli
    Department of Neurology, Mayo Clinic, Scottsdale, Arizona 85259, USA
    Sleep 29:927-33. 2006
    ..To test the hypothesis that healthy adults reporting dream-enactment behavior (DEB+) have reduced cerebral metabolic rate for glucose (CMRgl) in regions preferentially affected in patients with dementia with Lewy bodies (DLB)...
  61. ncbi Effects of ApoE genotype and mild cognitive impairment on implicit learning
    Selam Negash
    Mayo Clinic, Rochester, MN 55905, USA
    Neurobiol Aging 28:885-93. 2007
    ....
  62. ncbi Involvement of medullary regions controlling sympathetic output in Lewy body disease
    Eduardo E Benarroch
    Department of Neurology, Mayo Clinic, Rochester, MN 55905, USA
    Brain 128:338-44. 2005
    ..In LBD, orthostatic hypotension may be due primarily to involvement of sympathetic ganglion neurons rather than ventrolateral medulla neurons...
  63. pmc Mild cognitive impairment: ten years later
    Ronald C Petersen
    Department of Neurology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Arch Neurol 66:1447-55. 2009
    ..This review summarizes the progress that has been made while also recognizing the challenges that remain...
  64. pmc Symmetric corticobasal degeneration (S-CBD)
    Anhar Hassan
    Department of Neurology, Mayo Clinic, Rochester, MN, USA
    Parkinsonism Relat Disord 16:208-14. 2010
    ..Asymmetry is also emphasized on neuroimaging...
  65. ncbi Atypical progressive supranuclear palsy with corticospinal tract degeneration
    Keith A Josephs
    Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA
    J Neuropathol Exp Neurol 65:396-405. 2006
    ..The clinicopathologic features of these 12 cases expand the spectrum of 4R tauopathies...
  66. ncbi Neuropathologic features of amnestic mild cognitive impairment
    Ronald C Petersen
    Alzheimer s Disease Research Center and Department of Neurology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Arch Neurol 63:665-72. 2006
    ..The neuropathologic substrate of amnestic mild cognitive impairment (aMCI) is not known...
  67. pmc Clinicopathological and imaging correlates of progressive aphasia and apraxia of speech
    Keith A Josephs
    Department of Neurology, Division of Movement Disorders and Behavioral Neurology, Mayo Clinic, Rochester, MN 55905
    Brain 129:1385-98. 2006
    ..Refining the classification of the degenerative aphasias and AOS may be necessary to improve our understanding of the relationships among behavioural, pathological and imaging correlations...
  68. pmc Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease
    Clifford R Jack
    Clifford R Jack, Mayo Clinic, Diagnostic Radiology, 200 First Street SW, Rochester, MN 55905, USA
    Brain 132:1355-65. 2009
    ..This model implies a complimentary role for MRI and PIB imaging in Alzheimer's disease, with each reflecting one of the major pathologies, amyloid dysmetabolism and neurodegeneration...
  69. doi Utility of the DRS for predicting problems in day-to-day functioning
    Julie A Fields
    Department of Psychiatry and Psychology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Clin Neuropsychol 24:1167-80. 2010
    ..Functional impairments were noted even at mild levels of cognitive impairment. The DRS is helpful for determining the level of assistance that is likely needed in daily care and planning future care needs...
  70. pmc The treatment of parasomnias with hypnosis: a 5-year follow-up study
    Peter J Hauri
    Sleep Disorders Center, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    J Clin Sleep Med 3:369-73. 2007
    ..This study involves a replication and extension of a previous one reported by Hurwitz et al (1991) on the treatment of certain parasomnias with hypnosis...
  71. ncbi Dementia with Lewy bodies may present as dementia and REM sleep behavior disorder without parkinsonism or hallucinations
    Tanis J Ferman
    Department of Psychiatry and Psychology, Mayo Clinic and Foundation, Jacksonville, Florida 32224, USA
    J Int Neuropsychol Soc 8:907-14. 2002
    ..This provides further evidence in support of including RBD as one of the core diagnostic features of DLB...
  72. pmc 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment
    Clifford R Jack
    Department of Diagnostic Radiology, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Brain 131:665-80. 2008
    ..PiB and MRI provided complementary information such that clinical diagnostic classification using both methods was superior to using either in isolation...
  73. ncbi Hypocretin (orexin) levels in cerebrospinal fluid of patients with narcolepsy: relationship to cataplexy and HLA DQB1*0602 status
    Lois E Krahn
    Mayo Clinic, Department of Psychiatry and Psychology, Rochester, MN 55905, USA
    Sleep 25:733-6. 2002
    ..5%) and more specifically with patients with cataplexy who are HLA DQB1*0602 positive (95.7%). The relationship between hypocretin-1 levels and narcolepsy without cataplexy or the DQB1*0602 allele is less clear...
  74. ncbi Vascular dementia in a population-based autopsy study
    David S Knopman
    Department of Neurology, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Arch Neurol 60:569-75. 2003
    ..The validity of the clinical diagnosis of vascular dementia (VaD) remains suboptimal...
  75. pmc Association of duration and severity of diabetes mellitus with mild cognitive impairment
    Rosebud O Roberts
    Department of Health Sciences Research, Division of Epidemiology, College of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Arch Neurol 65:1066-73. 2008
    ..It remains unknown whether diabetes mellitus (DM) is a risk factor for mild cognitive impairment (MCI)...
  76. ncbi Undetectable CSF hypocretin-1 in "Hashimoto's encephalopathy" associated with coma
    Pablo R Castillo
    Sleep Disorders Center, Mayo Clinic, Jacksonville, FL 55905, USA
    Neurology 62:1909. 2004
  77. ncbi De novo genesis of neuropsychiatric symptoms in mild cognitive impairment (MCI)
    Yonas E Geda
    Department of Psychiatry and Psychology, Mayo Clinic Rochester, MN 55905, USA
    Int Psychogeriatr 16:51-60. 2004
    ..There is inadequate information regarding the neuropsychiatric aspect of Mild Cognitive Impairment (MCI)...
  78. pmc Hippocampal volumes, proton magnetic resonance spectroscopy metabolites, and cerebrovascular disease in mild cognitive impairment subtypes
    Kejal Kantarci
    Department of Diagnostic Radiology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Arch Neurol 65:1621-8. 2008
    ..Noninvasive imaging surrogates for underlying pathological findings in MCI would be clinically useful for identifying patients who may benefit from disease-specific treatments at the prodromal stage of dementia...
  79. pmc Very early semantic dementia with progressive temporal lobe atrophy: an 8-year longitudinal study
    Kathrin Czarnecki
    Department of Neurology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Arch Neurol 65:1659-63. 2008
    ..Semantic dementia is a syndrome within the spectrum of frontotemporal lobar degenerations characterized by fluent progressive aphasia (particularly anomia) and loss of word meaning...
  80. pmc Antemortem differential diagnosis of dementia pathology using structural MRI: Differential-STAND
    Prashanthi Vemuri
    Department of Radiology, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Neuroimage 55:522-31. 2011
    ..8%). The proposed approach establishes a direct a priori relationship between specific topographic patterns on MRI and "gold standard" of pathology which can then be used to predict underlying dementia pathology in new incoming patients...
  81. pmc Clinical characterization of a kindred with a novel 12-octapeptide repeat insertion in the prion protein gene
    Neeraj Kumar
    Department of Neurology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Arch Neurol 68:1165-70. 2011
    ..To report the clinical, electroencephalographic, and neuroradiologic findings in a kindred with a novel insertion in the prion protein gene, PRNP...
  82. pmc Mild cognitive impairment associated with limbic and neocortical Lewy body disease: a clinicopathological study
    Jennifer Molano
    Mayo Clinic, Rochester, MN 55905, USA
    Brain 133:540-56. 2010
    ....
  83. ncbi Proton MR spectroscopy in mild cognitive impairment and Alzheimer disease: comparison of 1.5 and 3 T
    Kejal Kantarci
    Department of Diagnostic Radiology, Milwaukee, WI, USA
    AJNR Am J Neuroradiol 24:843-9. 2003
    ..5 and 3 T to diagnostically discriminate among cognitively normal elderly subjects, patients with mild cognitive impairment (MCI), and patients with Alzheimer disease (AD)...
  84. ncbi Prospective study of quality of life in adults with newly diagnosed high-grade gliomas
    Paul D Brown
    Division of Radiation Oncology, Mayo Clinic, Rochester, MN 55905, USA
    J Neurooncol 76:283-91. 2006
    ..To assess baseline quality of life (QOL) and its prognostic importance for adults with newly diagnosed high-grade gliomas, we analyzed QOL and outcome data prospectively collected in three phase II high-grade glioma protocols...
  85. pmc The Mayo Clinic Study of Aging: design and sampling, participation, baseline measures and sample characteristics
    Rosebud O Roberts
    Division of Epidemiology, College of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Neuroepidemiology 30:58-69. 2008
    ..The objective of this study was to establish a prospective population-based cohort to investigate the prevalence, incidence and risk factors for mild cognitive impairment (MCI) and dementia...
  86. ncbi Alzheimer's disease patients' cognitive status and course years prior to symptom recognition
    Jane H Cerhan
    Mayo Clinic College of Medicine Rochester, Minnesota, USA
    Neuropsychol Dev Cogn B Aging Neuropsychol Cogn 14:227-35. 2007
    ..A significant interaction (but no group effect) was seen for verbal comprehension...
  87. ncbi Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease
    Neill R Graff-Radford
    Department of Neuroscience, Mayo College of Medicine, Mayo Clinic, 4500 San Pablo Rd, Jacksonville, FL 32224, USA
    Arch Neurol 64:354-62. 2007
    ..To develop preventive therapy for Alzheimer disease (AD), it is essential to develop AD-related biomarkers that identify at-risk individuals in the same way that cholesterol levels identify persons at risk for heart disease...
  88. ncbi What more can we learn from studying the REM sleep behaviour disorder-Parkinson's disease association?
    Bradley F Boeve
    J Neurol Neurosurg Psychiatry 79:1087. 2008
  89. pmc Voxel-based morphometry in autopsy proven PSP and CBD
    Keith A Josephs
    Department of Neurology Movement Disorders, Mayo Clinic, Rochester, MN 55905, USA
    Neurobiol Aging 29:280-9. 2008
    ..These results show regional differences between PSP and CBD that are useful in predicting the underlying pathology, and help to shed light on the in vivo distribution of regional atrophy in PSP and CBD...
  90. pmc Visual hallucinations in posterior cortical atrophy
    Keith A Josephs
    Divisions of Movement Disorders and Behavioral Neurology, Department of Neurology, Mayo Clinic, Rochester, Minn, USA
    Arch Neurol 63:1427-32. 2006
    ..It is not known, however, whether patients who meet the criteria for PCA and have hallucinations are different from those who meet the criteria and do not have hallucinations...
  91. pmc Beta-amyloid burden is not associated with rates of brain atrophy
    Keith A Josephs
    Department of Neurology, Mayo Clinic, Rochester, MN 55905, USA
    Ann Neurol 63:204-12. 2008
    ..To test the hypothesis that beta-amyloid (Abeta) burden is associated with rates of brain atrophy...
  92. ncbi Mutations in progranulin explain atypical phenotypes with variants in MAPT
    Stuart M Pickering-Brown
    Brain 129:3124-6. 2006
    ..Here, we demonstrate that the MAPT variants are almost certainly rare benign polymorphisms as all of these cases harbour mutations in Progranulin (PGRN). Mutations in PGRN were recently shown to cause ubiquitin-positive FTDP-17...
  93. ncbi Parkinson disease neuropathology: later-developing dementia and loss of the levodopa response
    Hulya Apaydin
    Department of Neurology, Istambul University, Cerrahpasa Medical School, Turkey
    Arch Neurol 59:102-12. 2002
    ..To investigate the neuropathologic substrate for dementia occurring late in Parkinson disease (PD)...